Chemistry:PF-592,379

From HandWiki
Short description: Dopamine receptor agonist compound
PF-592,379
PF-592379 structure.png
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Investigational (discontinued)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC13H21N3O
Molar mass235.331 g·mol−1
3D model (JSmol)

PF-592,379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which is under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction. Unlike some other less selective D3 agonists, a research study showed that PF-592,379 has little abuse potential in animal studies, and so was selected for further development and potentially human clinical trials.[1][2] Development has since been discontinued.[3]

See also

References

  1. "Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human". Xenobiotica; the Fate of Foreign Compounds in Biological Systems 40 (11): 730–42. November 2010. doi:10.3109/00498254.2010.514961. PMID 20836725. 
  2. "Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats". Behavioural Pharmacology 23 (3): 280–91. June 2012. doi:10.1097/FBP.0b013e3283536d21. PMID 22470105. 
  3. "Drug Profile: PF 592379". Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800025529.